search

Active clinical trials for "Spinocerebellar Degenerations"

Results 1-10 of 91

Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3. A total of 40 participants with SCA3 will be recruited, with 20 participants to be administered with trehalose while another 20 participants to be administered with a maltose placebo.

Recruiting10 enrollment criteria

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 31 more

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

Recruiting24 enrollment criteria

rTMS Improves Functions in Spinocerebellar Ataxia

Transcranial Magnetic StimulationSpinocerebellar Ataxias

Spinocerebellar ataxia (SCA) is a group of inherited brain disorders. SCA often result in poor limb coordination. This study aims to discover the effects of repeated transcranial magnetic stimulation (rTMS) on balance & gait in SCA. The hypothesis of this study is that rTMS might improve SCA limb functional performance.

Recruiting9 enrollment criteria

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia

Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 23 more

PRIME-Ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth intervention of low intensity exercise prior to balance training in people with spinocerebellar ataxias (SCAs). The investigators additionally aim to explore changes in motor skill learning on a novel motor skill task in a sub-group of participants pre and post intervention.

Active13 enrollment criteria

Trial in Adult Subjects With Spinocerebellar Ataxia

Spinocerebellar AtaxiasSpinocerebellar Ataxia Genotype Type 16 more

The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

Active12 enrollment criteria

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia...

Spinocerebellar Ataxia Type 3

Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).

Active24 enrollment criteria

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Spinocerebellar AtaxiasSpinocerebellar Ataxia Type 16 more

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

Active16 enrollment criteria

Open Pilot Trial of BHV-4157

Spinocerebellar AtaxiasSpinocerebellar Ataxia Type 14 more

24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia. BHV-4157 is a pro-drug of riluzole (which is currently FDA-approved for ALS, Lou Gehrig's disease). There will be 5 visits to UCLA required--Screening when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; Baseline when general and neurological examination and questionnaires will be administered and study drug dispensed; Week 4 and Week 12 when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; 2 weeks after finishing study drug when general examination and blood testing will be completed. There is an option for a 36 week extension of the study drug trial.

Active27 enrollment criteria

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 22 more

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as Machado-Joseph disease and SCA 6). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease. The research questions are: How does your disease progress over time? What are the best ways to measure the progression? Do some genes, other than the gene that is abnormal in your disease, have any effect on the way the disease behaves? This is a nationwide study and we expect that 800 patients will participate all over the USA. The participants will be in the study for an indeterminate period of time. Study visits will be done every 6 or 12 months depending on the participating site.

Recruiting7 enrollment criteria

Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar...

Cerebellar AtaxiaSpinocerebellar Ataxias1 more

The aim of the research is to improve motor function in people with cerebellar ataxia by using neuroimaging methods and mental imagery to "exercise" motor networks in the brain. The relevance of this research to public health is that results have the potential to reduce motor deficits associated with cerebellar atrophy, thereby enhancing the quality of life and promoting independence.

Recruiting12 enrollment criteria
12...10

Need Help? Contact our team!


We'll reach out to this number within 24 hrs